Everest Medicines' Licensing Partner NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study
VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitor Topline Phase 2a data show VIS-101 provides rapid, robust and durable treatment responses in wet AMD VIS-101 demonstrated...
Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025
– New findings demonstrate a 72% HI-E response rate at Week 16 with meaningful hemoglobin improvement – – Strong activity observed across ESA-refractory and ESA-intolerant patients, and across mutation and morphology subtypes – – Favorable safety...